---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-361705"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2026-08-24T10:01:23+00:00"
generated_at: "2026-08-24T10:05:05.949473+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytek jury verdict: noninfringement on 3 of 4 patent claims, $56.11M damages on 1 claim; appeal planned

## Summary
- Jury found for Cytek on 3 of 4 asserted claims (noninfringement and invalidity).
- One claim infringed under doctrine of equivalents; damages: $20M lost profits + $36.11M royalties.
- Cytek will pursue post-verdict motions and potential appeal to Federal Circuit.
- Verdict requires no changes to current products; spectral flow cytometry remains available globally.
- CEO Wenbin Jiang says Cytek developed fundamentally different Full Spectrum Profiling technology.

## SEC filing metadata
- accession: 0001193125-26-361705
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2026-08-24T10:01:23+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312526361705/0001193125-26-361705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312526361705/d137695d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-361705
- JSON: https://secwatch.observer/filing/0001193125-26-361705.json
- Plain text: https://secwatch.observer/filing/0001193125-26-361705.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.